Ixmyelocel-T: Phase II suspended enrollment

Aastrom suspended enrollment and patient treatment in the open-label, U.S. Phase II IMPACT-DCM trial of CRCs to treat DCM after a patient died at home following treatment in the trial. The cause of de...